DalCor Pharmaceuticals

DalCor Pharmaceuticals is a biopharmaceutical company focused on cardiovascular disease. A companion diagnostic developed with Roche Molecular Systems identifies patients with the ADCY9 AA genotype who may benefit from dalcetrapib treatment, and DalCor holds the worldwide exclusive license to develop, manufacture and commercialize dalcetrapib and the right to the ADCY9 AA genotype marker for use with it. The ADCY9 AA genotype occurs in up to 20% of the total population and in more than 40% of people with African ancestry.

The dal-GenE trial showed a 21% relative risk reduction in fatal and non-fatal myocardial infarction and a 45% relative risk reduction. Dalcetrapib targets patients with post-acute coronary syndrome who have the ADCY9 AA genotype.